RAS Blockade | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,686 results for “RAS Blockade”

Trials

View all 5341 →

RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough

104 participants · First posted Mar 6, 2013

RAS Quantification in Patients With Aliskiren or Candesartan

24 participants · First posted Apr 9, 2013

The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria

60 participants · First posted May 8, 2008

Drugs

View all 507 →

CD38 enzyme blockade

RAS-F3

RAS-001

Organizations

View all 220 →

Erasca

United States

Revolution Medicines, Inc.

United States

Ikena Oncology

United States

News

View all 3618 →

Concerns Raised Over Meta-Analysis Assessing Race and RAS Blockade in Heart Failure Trials

Adlai Nortye Advances First-in-Class Pan-RAS(ON) ADC AN4035 into Phase I Trial for RAS-Addicted Solid Tumors

ICAM1 Blockade Enhances Ischemic Muscle Reperfusion in Diabetic Mice

Page 1 of 969